Quidel (QDEL)

Quidel (QDEL)

Postby winston » Thu Apr 02, 2020 7:59 pm

not vested

PROVIDING TESTING IN THE GLOBAL FIGHT AGAINST CORONAVIRUS

Today, we're highlighting a company that's ready to combat the COVID-19 crisis...

As coronavirus sweeps across America, the number of U.S. cases has grown to more than 200,000. Medical equipment and supplies are crucial to treat the influx of patients.

But diagnostic tests also play an important role – so that states can understand where we stand and where outbreaks are happening. Today's company recently got the green light to distribute its tests in America...

Quidel (QDEL) is a leading maker of diagnostic solutions, such as tests. Its products help clinicians quickly diagnose infectious diseases and more.

As you've seen on the news, medical supplies – including masks, ventilators, and tests – are desperately needed by hospitals throughout the country.

And on March 17, the FDA gave emergency authorization for Quest Diagnostics (DGX) and Quidel to distribute tests for COVID-19.

QDEL shares jumped 26% that day as a result, and then went on to reach new highs. With the overall market swinging wildly with uncertainty, one thing's for certain...

We need tests to combat this pandemic. And that should drive further gains for this stock...

Source: Daily Wealth
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Quidel (QDEL)

Postby investar » Thu Apr 09, 2020 4:32 am

Bought some DGX today. Might hold for the LT. QDEL is still on the watchlist
investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm

Re: Quidel (QDEL)

Postby investar » Sat Apr 25, 2020 4:34 am

DGX doing well, but I should have bought QDEL at the time: +30% in three weeks

Since yesterday, Belgian Biocartis BCART.BR also entered the arena for Covid testing:

Biocartis Announces Development of Idylla™ COVID-19 test


Mechelen, Belgium, 23 April 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the development of a SARS-CoV-2 test, the virus that causes COVID-19, on the fully automated, rapid and easy to use molecular diagnostics platform Idylla™.

Upon regulatory approval, the Idylla™ SARS-CoV-2 test is targeted to help healthcare providers manage the COVID-19 pandemic through rapid and easy testing of individuals with flu-like symptoms. In addition, the Idylla™ SARS-CoV-2 test may be used in combination with the recently CE-marked IVD SeptiCyte® RAPID Test1 on Idylla™ to facilitate the management of patients within the hospital intensive care unit (ICU). When used together, this combined testing solution on Idylla™ has the unique potential to identify patients with severe disease, as recent data2 indicate that sepsis is the most frequently observed complication in COVID-193. Biocartis develops the Idylla™ SARS-CoV-2 test with support from multiple undisclosed partners as part of a joint commitment to respond to the COVID-19 pandemic.
investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm

Re: Quidel (QDEL)

Postby investar » Sun May 10, 2020 5:34 pm

Emergency FDA approval:

https://finance.yahoo.com/news/quidel-r ... 09791.html

Quidel (QDEL) has now received Emergency Use Authorization (EUA) from the US FDA for its Sofia 2 SARS Antigen FIA, a rapid point-of-care test for suspected COVID-19 infection.

According to the FDA, this is a new category of tests that will now be available for use in the ongoing pandemic. “The antigen diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs” the FDA says.

One of the main advantages of an antigen test is the speed of the test, which can provide results in minutes. However, antigen tests may not detect all active infections, as they are less sensitive than molecular PCR tests.

This means that negative results from an antigen test may need to be confirmed with a PCR test prior to making treatment decisions or to prevent the possible spread of the virus due to a false negative, the administration added.

Notably, antigen tests can generally be produced at a lower cost than PCR tests, the FDA stated, and once multiple manufacturers enter the market, can potentially scale to test millions of people per day due to their simpler design.

“I am tremendously proud of our organization’s ability to quickly develop and mobilize an accurate rapid antigen test,” said Douglas Bryant, Quidel's CEO. “The EUA for our Sofia 2 SARS Antigen FIA allows us to arm our healthcare workers and first responders with a frontline solution for COVID-19 diagnosis, accelerating the time to diagnosis and potential treatment of COVID-19 for the patient.”

The test is now available for sale in the US and is being shipped to customers.

Shares in Quidel have put on a dramatic rally recently, more than doubling year-to-date. However the stock has a Hold analyst consensus, while the $90 average analyst price target indicates downside potential of over 40%
investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm

Re: Quidel (QDEL)

Postby investar » Tue Oct 27, 2020 4:16 am

QDEL keeps going...

Today +7% again; on an otherwise UGLY day for the markets

Back to ATH of early August of +300$?
investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm


Return to L to R

Who is online

Users browsing this forum: No registered users and 7 guests

cron